Smith & Nephew PLC Sponsored ADR Stock

$25.15

0.63% yesterday

NYSE, Nov 25, 10:00 pm CET

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Smith & Nephew PLC Sponsored ADR Stock price

$25.15

-19.66 43.87% 5Y

NYSE, Closing price Mon, Nov 25 2024

-0.16 0.63%

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$10.97b
Enterprise Value	$14.05b
P/E (TTM) P/E ratio	36.03
EV/FCF (TTM) EV/FCF	46.91
EV/Sales (TTM) EV/Sales	2.50
P/S ratio (TTM) P/S ratio	1.95
P/B ratio (TTM) P/B ratio	2.11
Dividend yield	2.98%
Last dividend (FY24)	$0.75
Revenue growth (TTM) Revenue growth	2.60%
Revenue (TTM) Revenue	$5.62b
EBIT (operating result TTM) EBIT	$828.44m
Free Cash Flow (TTM) Free Cash Flow	$299.56m
EPS (TTM) EPS	$0.70
P/E forward	24.87
P/S forward	1.90
EV/Sales forward	2.43
Short interest	0.16%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Smith & Nephew PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

19 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

10x Buy

53%

9x Hold

47%

More details on Analyst Estimates Including Price Targets

19 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

Buy

53%

Hold

47%

Analyst Estimates with Stock Price Targets

Financial data from Smith & Nephew PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	5,620 5,620	3% 3% 100%
- Direct Costs	1,740 1,740	6% 6% 31%
Gross Profit	3,880 3,880	1% 1% 69%
- Selling and Administrative Expenses	2,087 2,087	4% 4% 37%
- Research and Development Expense	309 309	11% 11% 5%
EBITDA	1,484 1,484	13% 13% 26%
- Depreciation and Amortization	656 656	6% 6% 12%
EBIT (Operating Income) EBIT	828 828	19% 19% 15%
Net Profit	304 304	38% 38% 5%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Smith & Nephew PLC Sponsored ADR Stock News

Negative

Reuters

●

12 days ago

Big investors call for break-up of Smith & Nephew, FT reports

Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.

Positive

Seeking Alpha

●

16 days ago

Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends

Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound manag...

Neutral

Seeking Alpha

●

24 days ago

Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript

Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lis...

More Smith & Nephew PLC Sponsored ADR News

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Deepak Nath
Employees	19,551
Founded	1856
Website	www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now